Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer

NCT03373188 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03373188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03373188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
December 15, 2017
Completion date
October 28, 2021
Enrollment
10 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colon carcinoma metastatic in the liver, colorectal adenocarcinoma, pancreatic adenocarcinoma, resectable pancreatic carcinoma, stage i pancreatic cancer, stage ia pancreatic cancer, stage ib pancreatic cancer, stage ii pancreatic cancer, stage iia pancreatic cancer, stage iib pancreatic cancer, stage iii pancreatic cancer, stage iv colorectal cancer, stage iva colorectal cancer, stage ivb colorectal cancer